Author Index, Volume 92, 1997

*Indicates a Book Reviewer
S indicates Supplement issues (March & June)

Abdul-Quader, A. S., 813
Abrams, D. B., 1717
Addington, J., 805
Addolorato, G., 1035
Adlaf, E. M., 1793*
Aitchison, T., 313
Al-Adawi, S., 1773
Albery, I. P., 113
Ali, R., 1790*
Allsop, S., 61
Alonso, J., 707
Amodei, N., 1705
Amundsen, A., 903
Anderson, H. R., S3, 1765
Andrew, S. R., 1705
Arai, Y., 1023
Archibald, C. P., 1339
Arciniega, L. T., 601, 1619
Ashley, M. J., S109

Babor, T. F., 951, 1087, 1237, 1613, 1665
Balaji, M., 1783
Balfour, D. J. K., 615
Barber, N., 1737
Barnard, M., 1317
Barrio, G., 1749
Basu, D., 1783
Batey, R. G., 1189
Batki, S. L., 297
Beattie, M. C., 1507
Bell, R., 571
Bell, R. M., 1123
Benowitz, N. L., 347, 615
Bergman, B., 1183
Berkowitz, G., 765*
Berney, L., 419
Berridge, V., 253, 965
Berry, G., 667
Best, D., 353
Bevan, J., 1081
Bierut, L. J., 889
Bigelow, C., 1467
Bland, M., 1749
Blasz :zynski, A., 75
Blow, F. C., 583
Bolinder, G., 525, 1071
Borland, R., 1151, 1361, 1427
Bourgault, C., 303
Bower, C. I., 1553, 1561
Bowman, J. A., 1412
Boys, A., 1327
Brady, N. M., 459
Bravo, M. J., 1749
Breitbart, V., 1201
Bremner, K. E., 969
Breslin, F. C., 1479
Bruce, M., 1729
Buchan, G., 1479
Bucholz, K. K. 889, 1289
Bunt, L. J., 1491
Burge, S. K., 1705
Burns, L., 1038*
Burton, S. M., 15
Byrne, A., 220

Calsyn, D., 1037*
Cantor, S. B., 197
Cappiello, M., 1361
Caputo, F., 1035
Carpenter, K. M., 747
Carr, A., 61
Casswell, S., S81, 737
Castillo, C., 707
Catala, S., 1705
Caulkins, J. P., 1143, 1437
Cavin, S. W., 473
Chapman, S., 607
Chatterjee, A., 813
Chavkin, W., 1201
Chick, J., 953
Chilcoat, H. D., 491*
Collins, R. L., 1376*
Colom, J., S21
Cone, E. J., 717
Cook, C. C. H., 381, 539, 793
Cornelisse, P. G. A., 1339
Courtwright, D. T., 257
Coutinho, R. A., 1457
Coyle, D., 1007
Craplet, N., S103
Crofts, N., 999
Crowe, R. R., 1289
Croxson, T. S., 167
Cunningham, J. A., 1479
Curran, H. V., 821

Darke, S., 697, 1037*, 1195
Dawson, D., 1792*
De Almeida Neto, A., 27
De Burgh, S., 667
De la Fuente, L., 1749
Deb, B. C., 813
Del Rio, M., 1353
Delucchi, K. L., 297
Demers, A., 303
Devlin, N. J., 1491
DeYoung, D. J., 989
Dinwiddie, S. H., 889
Dolinsky, Z. S., 1087
Domingo-Salvany, A., 707
Dongier, M., 969
Drop, M. J., 49
Drummond, D. C., 375, 939, 961
Dubois, G., S109
Dunn, J., 354
Dunne, M. P., 889
Dyer, K. R., 1445

Edwards, A. G. K., 1699
Edwards, G., 223*, S73, 1045, 1613, 1794*
Eisen, S. A., 409, 1277
El-Guebaly, N., 805
Elkin, B., 1705
Elliot, L., 1349

English, D. R., 1547, 1553, 1561, 1571
Esmail, A., 1765
Evans, K. R., 1207

Fabricius, W. V., 847
Feigelman, W., 493*
Fennema, J. S. A., 1457
Fergusson, D. M., 279
Finch, E., 492*
Fiore, M. C., 469
Fischer, B., 1791*
Fitzgerald, J. L., 1099
Flaherty, B., 173
Forsyth, A. J. M., 1317
Foulds, J., 763*
Foxcroft, D. R., 531
Frederick, S. L., 89
Freels, S. A., 437
Frischer, M., 419
Frost, R., 1467
Fukao, A., 1023

Gable, R. S., 1179
Galloway, G. P., 89
Garfield, F., 1467
Garretsen, H. F. L., 335
Gasbarrini, G., 1035
Gelb, A. M., 167
Gillman, M. A., 1035
Gilpin, E., 473
Giovino, G. A., 469
Godfrey, C., S49, 612, 762*, 1007
Goldbeck, R., 313
Goldberg, D., 419
Goldberg, J., 409, 1277
Goldstein, A., 1241, 1789*
Gonzales, M., 89
Gossop, M., 353, 673, 692
Grant, K. A., 601
Green, A. I., 409
Greenfield, T. K., 33
Griffiths, P., 673, 692
Grube, J. W., S155, S251, S293
Gruenewald, P. J., S155, S221, S261, S273, S293, 859
Gruer, L., 1349
Gual, A., S21
Gunning, W. B., 871

Haddad, S., 607
Hajema, K-J., 49
Hall, W., 373, 697, 1109, 1195
Hamilton, M., 1099
Hando, J., 173
Hangzo, C., 813
Hannifin, J., 687
Hansen, S. S., 429
Hardman, G., 1007
Hartwell, N., 1017
Hatsukami, D. K., 651
Hausser, D., 325
Hawks, D., 490*, 1081, 1175
Heath, A. C., 889, 1277
Heath, D. B., 489*
Heather, N., 229, S133
Heishman, S. J., 615
Hendriks, V. M., 335
Henningfield, J. E., 691
Hesselbrock, V., 1289
Hill, D., 1151
Hill, E. M., 583
Hirsch, C. S., 1017
Hisamichi, S., 1023
Hittner, J. B., 747
Hodgins, D. C., 805
Holder, H. D., 5, S117, S155, S173, S189, S221, S261, S285, S293, 859
Holder, S., 1613
Holman, C. D. J., 1547, 1553, 1561, 1571
Holzer, C. E. III, 197
Hoogeveen, K-J., 871
Horwood, L. J., 279
Hosokawa, T., 1023
Hourigan, M., 1159
Hughes, H., 137
Hughes, J. C., 381
Hughes, J. R., 469
Hulse, G. K., 1547, 1553, 1561, 1571
Hunt, N., 219
Hurt, R. D., 521

Izumi, Y., 1023

Jack, L. M., 207
Jacob, P. III, 347
Jacobson, P. D., 1123
Jang, K. L. 1265
Johnson, S. L., 224*
Johnson, T. P., 437
Johnston, L. D., 571
Jones, R. T., 297

Kalant, H., 267, 689, 1371*
Karlsson, G., 447
Kehoe, L., 27
Keso, L., 483
Kleiman, M. A. R., 764*
Klevens, R. M., 469
Knibbe, R. A., 49
Kramer, J., 1289
Kranzler, H. R., 951
Kreek, M. J., 167
Kuebler, D., 325

Lam, L. C. W., 685
Lane, P. A., 1705
Latkin, C. A., 1377*
Law, F., 1040*
Legl, T., 163
Lehofer, M., 163
Lehto, J., S55, S91
Leifman, H., 1523
Leischow, S. J., 347
Lemmens, P. H., 1077
Lenton, S., 1327
Leon, A. C., 1017
Lichtigfeld, F. J., 1035
Liebmann, P. M., 163
Lin, N., 1277
Lind, B., 557
Lindstrom, J. M., 615
Lister-Sharp, D., 531
Littleton, J., 960
Livesley, W. J., 1265
Longabaugh, R., 1507
Lowe, G., 531
Loxley, W., 1081
Lyons, M. J., 409, 1277

MacKinnon, D. P., 847
MacPherson, J., 459
Madden, P. A. F., 889
Mäkelä, K., 729
Malhotra, A., 1783
Mann, R. E., 9
Marmot, M., S13
Marsden, J., 353
Martin, N. G., 889
Martin, R. A., 1717
Martinez, A., 707

Marzuk, P. M., 1017
Mattick, R. P., 151, 223*, 484, 839
Mattoo, S. K., 1783
Mayes, L. C., 1373*
McCall, M., 597
McConaghy, N., 75
McCusker, J., 1467
McKeganey, N. P., 1317
Meerkerk, G-J., 335
Meyer, J. M., 409
Meyers, R. J., 601
Michalec, E., 1717
Millar, A. B., S273
Miller, W. M., 485, 486
Miller, W. R., 601, 1639
Milne, E., 1547, 1553, 1561, 1571
Mino, A., 1353
Moncrieff, J., 939, 961
Monti, P. M., 1717
Montonen, M., S121
Moos, R. H., 481
Morrison, A., 1349
Moser, M., 163
Mosher, J. F., 789
Moskalewicz, J., S97
Mudd, S. A., 583
Myatt, P., 313

Nagoshi, C. T., 847
Naranjo, C. A., 969
Newman, T., 1165
Ng-Mak, D., 1305
Nigro, L., 999
Nilsson, F., 347
Norcross, K., 1327
Novick, D. M., 167
Nurnberger, J. I., 1289
Nutt, D. J., 958
Nuttbrock, L., 1305

Ockene, J. K., 615
Ofner, M., 1339
Olmstead, R. E., 347
O'Malley, S. S., 950
Oman, K., 999
O'Shaughnessy, M. V., 1339
Owen, N., 1361

Pacurucu-Castillo, S., 686
Page, P. B., 1619
Parrott, A., 523
Parsons, J. A., 437
Patrick, D. M., 1339
Patterson, D. G., 459
Pentz, M. A., 1165
Perecy, A., 931
Perkins, K. A., 517, 528
Perneger, T. V., 1353
Pernhaupt, G., 163
Peters, D., 1649, 1667
Phillips, M., 61
Pickworth, W. B., 691
Pierce, J. P., 473
Poikolainen, K., 903, 904
Poldrugo, F., 1537
Pomerlau, C. S., 397
Ponicki, W., 859
Portera, L., 1017
Powell, J., 1773
Preston, K. L., 717
Prestwich, P. E., 1255
Project MATCH Research Group, 1671

Rahav, M., 1305
Rahman, M., 419
Raistrick, D., 1007
Ramsay, M., 931
Ramsey, J., 1765
Raven, M., 492*
Reagan, K. J., 167
Rehm, J., S109
Rekart, M., 1339
Reuter, P., 611, 1143
Reynolds, R. I., S261
Richmond, R. L., 27, 1137
Ritson, B., S127, 1039*
Rivera, J., 1305
Robson, P., 1729
Roche, A., 761*, 1207
Rohsenow, D. J., 1717
Roizen, R., 221
Rollnick, S., 1699
Romelsjö, A., 447, 859, 1523
Room, R., 33, S7
Rose, J. E., 524
Ross, H., 183
Ross, J., 697
Ross, L. T., 583
Rossow, I., 903
Royuela, L., 1749
Rutter, S., 173

Salaspuro, M., 483
Saltz, R. F., S155, S237, S293
San, L., 688, 707, 1375*
Sanson-Fisher, R. W., 1411
Sarkar, S., 813
Saunders, B., 61
Saxena, S., S43
Schauenstein, K., 163
Schechter, M. T., 1339
Scherrer, J. F., 1277
Schneider, N. G., 347
Schuckit, M. A., 979, 1289
Schuster, C. R., 717
Schütz, C., 1369
Scuffham, P. A., 1491
Seale, J. P., 1705
Sergeant, J. A., 871
Shakeshaft, A. P., 1423
Sharma, A., 1783
Sheridan, J., 833, 1737
Sherman, J., 999
Shiffman, S., 527
Shirley, M., 183
Silverman, K., 717
Simpura, J., S33
Sindhusake, D., 607
Slama, K., 522
Slutske, W. S., 889
Smart, R. G., 9
Smith, D. E., 89
Smith, T. L., 979
Sobell, L. C., 1479
Sobell, M. B., 1479
Soyka, M., 956, 1369
Speiglman, R., 1133
Spilich, G. J., 1423
Spotts, D., 1467
Staggers, F. E., 89
Stalcup, S. A., 89
Stanton, W. R., 1207
Statham, D. J., 889
Staussner, S. L. A., 225*
Steel, Z., 75
Stefanini, G. F., 1035
Steinbauer, J. R., 197
Stenger, R. J., 167
Stevenson, E., 999
Stockwell, T., 925
Strang, J., 353, 673, 692, 833, 1737
Stranghetta, P., 237
Strathdee, S. A., 1339
Sulkunen, P., 1117

Sussman, S., 1165
Swan, G. E., 207
Świątkiewicz, S67

Tardiff, K., 1017
Taylor, C., 1737
Tiffany, S. T., 15
Tipp, J. E., 979, 1289
Tonigan, J. S., 601
Toomey, R., 409
Topp, L., 151, 839
Torrens, M., 707
Travill, R. A., 821
Treno, A. J., S155, S173, S189, S293
True, W. R., 409, 1277
Tsuang, M. T., 409, 1277
Turner, C., 1423
Tyrrell, T., 1405

Valentine, J. D., 1663
Van Ameijden, E. J. C., 1457
Van den Hoek, A., 1457
Van Oers, H. A. M., 335
VanGeest, J. B., 437
Vernon, P. A., 1265
Vickers-Lahti, M., 1467
Voas, R. B., S155, S201, S221, S293
Volk, R. J., 197

Wagner, H-B., 226*
Walker, D. D., 486
Walsh, B., S61
Warburton, B., 1765
Ward, M. M., 207
Warner, J., 97
Waterman, B., 1277
Watts, S., 492*
Weatherburn, D., 557
Wechsler, H., 571
West, R., 133, 1061, 1613
Westermeyer, J., 686
Westreich, L. M., 1374*
Wetter, D. W., 653
White, J., 1445
Wiers, R. W., 871
Wilkinson, L., 657
Wolfson, M., 1159

Zapotoczky, H. G., 163
Zellman, G. L., 1123
Zhang, J-F., 737
Zomi, G. T., 813
Zucker, R. A., 1664

Subject Index, Volume 92, 1997

The following abbreviations have been used in this index:
Ed Editorial
L Letter
S Supplement issues
* Book review
# News and Notes

Acamprosate for alcohol problems, 939–947, 949–964, 1537–1546
Accidents, benzodiazepines and elderly drivers, 1379*
Accidents involving alcohol
  aviation industry policies, 539–555, 793–804
  prevention, S117–S120, S155–S310
    community mobilization, S173–S187
    media advocacy, S189–S199
  responsibility, 1183–1188
see also Drink-driving
Addiction, 1037*, 1041*, 1789*
  and aromatherapy, 486–487(L)
  conferences, 355*
  costing services, 1005–1015
  dual diagnosis *see* Dual diagnosis
  ethical and policy issues, 1061–1226
    expert panel survey, 1061–1070
    responsibility of researchers, 1081–1085
  health service issues, 1189–1212
  historical aspects, 97–111, 137–149, 223*, 253–255(Ed), 257–265, 489*, 657–666, 673–683, 685–695, 1241–1254, 1405–1409(Ed), 1619–1637, 1792*
  and homelessness, 437–445
  Information Exchange, Leeds, 495#
  journals, 1639–1648
    consensus on editorial policies, 1613–1616(Ed), 1617–1618
  and psychotherapy, 226*
  publications, 231#, 356#
  research
    embargo policies, 1237–1239(Ed)
    ethical vs. legal responsibilities, 1081–1085
    funding, 1071–1107, 1423–1426
Addiction
  editorial review process, 949, 1613–1616(Ed), 1617–1618
  referees, 779–782
Addiction Research Foundation merger, 1044#
Addiction Research Institute research award, 1380#
Adolescents
  alcohol
    access and later drinking, 737–745
    'alcopops', 1043#
    attractiveness and accessibility, 597–600
    community-based purchase prevention, S251–S260
    drugs and rave music, 1317–1325
    expectancies, 871–888
    problems, 1039*
  drug prevention for minorities, 491*
  smoking
    anti-smoking campaign, 133–135(Ed)
    least harm vs. no smoking, 1165–1173
  substance abuse, 224*
see also Young people
Adult Attention Deficit Hyperactivity Disorder and smoking, 397–408
Advertising
  alcohol, 232#, S97–S101, S121–S125, 769#
  tobacco, 1582#
Agency for Health Care Policy and Research, 653–655(Ed)
AIDS/HIV infection
  drug injectors,
    community pharmacists' attitudes, 1737–1748
    contact tracing, 354(L)
    interventions, 813–820, 1377*
    needle sharing, 1339–1347
    overdose victims, 1017–1022
    risk behaviour, 906#, 1457–1465
  HIV-1 protease inhibitors and drug interactions, 905#
Alcohol
  and accidents *see* Accidents involving alcohol
  advertising, 232#, S97–S101, S121–S125, S769*

Alcohol (*cont*)
and aviation, 539–555, 793–804
consumption, 1040*
adolescents, 224*, 737–745, S251–S260, 1039*
'alcopops', 1043#
at risk identification, 197–206
and availability, 597–600, 737–745, S251–S260, S261–S272, 925–930(Ed)
beverage container labels, 789–792(Ed)
brief interventions, 375–379, S133–S136, 1699–1704
and craving to smoke, 15–26
and crime, S117–S120, 925–930(Ed), 1183–1188
cultural controls, S7–S11
decline in S. Europe, S21–S31
dose-harm relationship, S81–S90, S97–S101, S109–S115
and driving *see* Drink-driving
Europe, S3–S6(Ed), S21–S31, S91–S96
expectancies, 871–888
and family disruption, S117–S120
gender differences, 1265–1276
and health-related problems *see* Alcohol problems
imported beverages, S61–S66
majority fallacy, 729–736
measures, 667–672, 1380#
mortality, 903–904(L), 1523–1536
Netherlands, 49–60
personal safety, S117–S120
Poland, S67–S71, 1043#
protective effect, S97–S101, S109–S115
problems *see* Alcohol problems
questionnaires, 197–206, 979–988
server education trial, S155–S310
and social class, S13–S20, 903–904(L)
solitary drinking, 303–312
and speech, 1794*
Sweden, 859–870, 1523–1536
US *see* United States
and violence, 1183–1188
women *see* Women
workplace responses, S127–S132
economic aspects, S49–S71
education, 5–7(Ed), 9–13, S81–S90, S97–S101, S103–S108, S121–S125, S133–S136, 531–537, S189–S199, 1376*
history, 253–255(Ed)
Alcoholics Anonymous, 223*
cultural controls, S7–S11
temperance in Tudor England, 97–111
US prohibition, 1405–1409(Ed)
women's drinking, 1792*
industry and research funding, 1035(L)
international trade, S61–S66
policies, S73–S108, 925–930(Ed)
aviation safety, 539–555, 793–804
at community level, S285–S292, 1044#
developing countries, S43–S48
economic aspects, S55–S59, S97–S101
ethical aspects, 1117–1122, 1159–1164
Europe, S3–S6(Ed), S33–S41
harm reduction, 1207–1212
Ireland, 1043#
law enforcement, 1159–1164
Poland, S67–S71, 1043#
prevention policies, S73–S79, S155–S310, 1117–1122
pricing strategies, S13–S20
protective effect debate, S81–S90
Sweden, 859–870
problems, S3–S6(Ed), 1040*
costing studies, S49–S54
dose-risk relationship, S81–S90
effect of consumption changes, 1523–1536
Europe, S91–S96
prevention, 5–7(Ed), 9–13, S73–S79, S103–S108, 925–930(Ed), 1117–1122
and primary health care, S133–S136
and psychiatric disorders *see* Dual diagnosis
solitary drinking as risk factor, 303–312
research
behavioural studies, 1411–1422
consumption measures, 667–672
costing studies, S49–S54
ethical issues, 1087–1097
geographic data, S273–S283
industry supported, 1035(L), 1077–1079
E. M. Jellinek, 1619–1637
methodologies, 939–947, 949–964
reliability of self-reports, 601–606
research subjects, 1087–1097
see also Research methods
Alcohol Policy and the Public Good, S73–S79
Alcoholics Anonymous history, 223*
Alcoholism, 1041*
access to medical treatments, 1189–1193
children of alcoholics *see* Children of alcoholics
classification by statistical groups, 1649–1661, 1663–1669
community responses, S127–S132
gender-specific etiology, 1265–1276

Alcoholism (*cont*)
history *see* History
and psychiatric disorders *see* Dual diagnosis
social costs, 1491–1505
treatment, S97–S101, 1189–1193, 1375*
acamprosate, 939–947, 949–964, 1537–1546
Alcoholics Anonymous, 223*
attrition in general practice, 1699–1704
brief interventions, 1705–1716
community strategies, 459–468, 761*
costing services, 1007–1015
couple therapy, 492*
disulfiram review, 381–395
the elderly, 225*
GHB and craving, 89–96, 1035–1036(L)
health service issues, 1189–1212
individual interventions, 5–7(Ed), 9–13
matching clients to treatment, 1671–1698
new drug treatments, 939–947, 949–964, 969–978
New Zealand, 355*
outcome
interpersonal factors, 1507–1521
monitoring, 481–485(L)
self-efficacy as predictor, 313–324
relapse prevention, 61–74
single/mixed gender, 805–812
stepped care, 1479–1489
types, 1649–1661, 1663–1669
and women, 1201–1205, 1792*
workplace responses, S127–S132
'Alcopops', 1043#
American Council for Drug Education website, 1380#
Amphetamines
dependence, 151–162, 839–845
prescribing to drug users, 833–838
visible/invisible users, 1729–1736
Anxiety disorders and smoking, 397–408
Arab Association for the Prevention of Drugs and Addictions, 1582#
Aromatherapy for addiction, 486–487(L)
Aviation industry and alcohol, 539–555, 793–804
Australia
cannabis debate, 1109–1115
cocaine abuse, 173–182
heroin market, 557–569, 611–613(L)
injecting drug use, 906#
methadone maintenance and hepatitis C, 999–1005
Order of Australia to David Hawks, 1045
tobacco health warnings, 1151–1157, 1427–1435

Belorussia news, 495#
Benzodiazepines
and elderly drivers, 1379*
use by heroin users, 697–705
WHO report, 1581#
Biographies
E. M. Jellinek, 1619–1637
Marie Nyswander, 257–265
Sir Austin Bradford Hill, 657–666
Brain and addiction, 1789*
Brazil news, 232#
Bromocriptine for alcohol problems, 939–947, 949–964, 969–978
Bulimia and smoking, 397–408
Busipirone for alcohol problems, 939–947, 949–964

Canada
Addiction Research Foundation merger, 1044#
alcohol problems in Ontario, 9–13
smoking policies, 1044#
Cannabis
Australia, 1109–1115
and aviation, 539–555
early onset use and risks, 279–296
genetic vs. environmental reactions, 409–417
long-term use, 767#
maternal use and birthweight, 1553–1560
student use, 571–581
visible/invisible users, 1729–1736
'Chasing the dragon' origins, 673–683, 685–695
Children
of maternal addicts, 1201–1205, 1373*
substance abuse, 224*
see also Adolescents
Children of alcoholics
adulthood functioning, 583–596
alcoholism risks by retrospective reports, 979–988
China
ethics of tobacco provision, 1137–1141
and smoking, 905#
Cigarettes *see* Smoking
Cirrhosis of the liver *see* Liver disease
Citalopram for alcohol problems, 939–947, 949–964
Cocaine abuse
and abruptio placentae, 1547–1551

Cocaine abuse (*cont*)
in Australia, 173–182
coping skills treatment, 1717–1728
maternal use and birthweight, 1561–1570
quantitative outcome measures, 297–302
quantitative urinalysis, 717–727
trafficking, 764*
US crack and powder prices, 1437–1443
visible/invisible users, 1729–1736
Codeine cough syrup abuse, 1783–1787
Coronary heart disease and alcohol, S81–S90
Cough mixture abuse, 1783–1787
Crime
and alcohol, S117–S120, 925–930(Ed), 1183–1188
and drugs, 1038*

Denmark, drug abusers in mental hospitals, 429–435
Depression and smoking, 397–408
Developing countries
alcohol policies, S43–S48
ethics of tobacco provision, 1137–1141, 1380*
Disulfiram outcome review, 381–395
Doctors *see* General practice
Drink-driving, S97–S101, S117–S120, 925–930(Ed), 1183–1188
community prevention trial, S155–S310
evaluation, S221–S236
planning, S201–S219
efficacy of sanctions, 989–997
psychosocial conditions, 447–457
treatment policies, 1133–1136
Drugs, 1371*
concepts of drugs, 847–858
education, 491*, 1376*, 1793*
history, 253–255(Ed), 257–265, 489*, 673–683, 685–695, 765*
misuse, 1037*
access to treatment, 1189–1193
and aviation accidents, 539–555
at dance events, 1317–1325, 1327–1337
Europe, 231*
gender specific etiology, 1265–1276
harm minimization, 355#
Home Office Index, UK, 768#
and homelessness, 437–445
injecting behaviour and AIDS/HIV
community pharmacists' attitudes, 1737–1748
contact tracing, 354(L)
interventions, 813–820, 1377*
mortality, 1017–1022
needle sharing, 1339–1347
risk behaviour, 906#, 1457–1465
injectors
health problems, 1349–1352
and hepatitis C, 167–171
mortality, 419–427
and needlestick injuries, 219–220(L)
mortality, 419–427, 1017–1022
and musical preferences, 1317–1325, 1327–1337
Nexus 2CB, 114
and psychiatric disorders, *see* Dual Diagnosis
severity of dependence scale, 363(L)
smokable drugs, 673–683, 685–695
Swiss hidden population study, 325–334
UK *see* United Kingdom
US *see* United States
visible/invisible users, 1729–1736
women *see* Women
policies, 490*, 1109–1188, 1371*
Australia, 1109–1115
harm vs. use reduction, 1143–1150, 1207–1212
opportunity costs of prohibition, 1179–1182
US, 1143–1150, 1790*, 1791*
policing strategies, 557–569, 611–613(L), 1038*
research, ethical issues, 1081–1085, 1099–1107
treatment, 1189–1193
attrition among mentally ill, 1305–1315
costing services, 1007–1015
evidence-based, 373–374(L)
GHB and craving, 86–96, 1035–1036(L)
health problems of injectors, 1349–1352
health service issues, 1189–1212
methadone *see* Methadone
Nepal, 113#
planned duration and efficacy, 1467–1478
quantitative testing for outcome, 297–302
relapse of males, 61–64
single/mixed gender, 805–812
see also specific drugs
Drunkenness, habitual *see* Alcoholism
Dual diagnosis, 183–196, 226*, 429–435, 747–759, 1289–1304, 1305–1315, 1374*

Eating disorders and smoking, 397–408
Ecstasy *see* MDMA
Ecuador, 768#, 1375*

Education and training of doctors in prenatal drug use, 1123–1131
England *see* United Kingdom
Estonia, youth drinking, S121–S125
Ethanol *see* Alcohol
Europe
  alcohol issues, S21–S31, S33–S41, S91–S96
  conference on Health, Society and Alcohol S1–S152
  drug problem report, 231#
European Charter on Alcohol, S3–S6(Ed)
European Conference on Health, Society and Alcohol, S1–S12

Farmington Consensus, 1613–1616(Ed), 1617–1618
Fluoxetine for alcohol problems, 939–947, 949–964
France and alcohol
  consumption, S21–S31
  education, S121–S125
  Legrain and the temperance movement, 1255–1263

Gambling, 493*
  and impulsivity, 75–87
  at risk instant lottery players, 335–346
Gamma-hydroxybutyrate *see* GHB
General practice
  alcohol interventions, S133–S136, 1699–1704
  methadone maintenance, 1037*
Genetic factors in addiction, 1265–1276, 1277–1287
GHB, misuse and dependence, 89–96, 1035–1036(L)
Glasgow drug injectors' mortality, 419–427
Great Britain *see* United Kingdom
Greece, alcohol consumption, S21–S31

Hawks, David, Order of Australia, 1045
Health care expenditure
  naloxone for heroin users, 1195–1199
  restricting services for addicts, 1189–1193
Health education *see* Public health education
Health service issues, 1189–1212
Hepatitis C in drug users, 167–171, 999–1005
Heroin addiction
  and benzodiazepine use, 697–705
  'chasing the dragon' origins, 673–683, 685–695
  and decreased pain sensitivity, 163–166
  fashion industry, 1044#
  injecting to smoking, 1749–1763
  law enforcement and demand, 557–569, 611–613(L)
  maternal use and birthweight, 1571–1579
  naloxone provision, 1195–1199
  overdose, 1195–1199
  visible/invisible users, 1729–1739
  see also Methadone maintenance
History of addiction, 253–255(Ed)
  Alcoholics Anonymous, 223*
  'chasing the dragon' heroin smoking, 673–683, 685–695
  illegal drugs in US, 489*
  Jellinek and alcohol studies, 1619–1637
  Marie Nyswander, 257–265
  Paul-Maurice Legrain, 1255–1263
  Sir Austin Bradford Hill, 657–666
  temperance in Tudor England, 97–111
  US addictions, 137–149
  US prohibition, 1405–1409(Ed)
  women and addiction, 765*, 1792*
HIV infection *see* AIDS/HIV infection
Holland *see* Netherlands
Home Office Index, UK, 768#
Homelessness and substance abuse, 437–445
Hypnotics, propofol dependency, 1369–1370(L)

Impulsivity in gambling, 75–87
India
  codeine cough syrup abuse, 1783–1787
  HIV prevention, 813–820
Institute for the Study of Drug dependence website, 1380#
International Narcotics Control Board, 1582#
Internet, substance abuse sites, 1380#
Interviews
  Avram Goldstein, 1241–1254
  Senator Harold Hughes, 137–149
Ireland, National Alcohol Policy, 1043#
Israel, tobacco industry litigation, 1582#
Italy, alcohol consumption, S21–S31

Keller, Mark, 221(L)
Kettil Bruun Society, 768#

Liver disease, drugs and hepatitis C, 167–171
Legrain, Paul-Maurice, 1255–1263

Marijuana *see* Cannabis
MDMA, mood and cognitive effects, 821–831
Methadone maintenance, 1037*
  development by Marie Nyswander, 257–265

Methadone maintenance (*cont*)
and hepatitis C, 999–1005
HIV-1 protease and drug interactions, 905#
maternal use and birthweight, 1571–1579
measuring patients' health status, 707–716
patterns of symptom complaints, 1445–1455
predictors of patient retention, 1353–1360
safety, 220–221(L)
see also Heroin addiction
Musical preferences and drug use, 1317–1325, 1327–1337

Naltrexone for alcohol problems, 939–947, 949–964
National Centre for Treatment Development, New Zealand, 355#
Nepal, addiction treatment, 113#
Netherlands
alcohol consumption changes, 49–60
at risk instant lottery players, 335–346
New Zealand
cannabis use, 279–296
National Centre for Treatment Development, 355#
social costs of alcohol abuse, 1491–1505
Nexus/2CB abuse, 114#
Nicotine
replacement treatments
success rate of patches, 207–218
transdermal patch with therapy, 27–31
research, 615–633
withdrawal in women, 889–902
see also Smoking *and* Tobacco
Nociceptive sensitivity in opiate dependence, 163–166
Nottingham Health Profile for methadone patients, 707–716
Nurses and health care, S133–S136
Nyswander, Marie, and methadone maintenance, 257–265

Obituary, Fred Yates, 229
Opiates *see* Drugs *and specific opiates*
Opium review, 267–277

Physicians *see* General practice
Poland, alcohol issues, S67–S71, 1043#
Portugal, alcohol consumption, S21–S31
Preventing Alcohol Trauma Community Trial, S155–S310
Problem drinking *see* Alcoholism
Propofol dependence, 1369–1370(L)
Psychiatric disorders and addiction, 183–196, 226*, 429–435, 747–759, 1289–1304, 1305–1315, 1374*
Psychosocial problems and early cannabis use, 279–296
Public health education, 1175–1177
alcohol, S81–S90, S155–S310, 531–537, 1117–1122, 1159–1164
prevention approaches, S155–S310, 1159–1164, 1376*, 1377*
smoking, 133–135(Ed), 1044#, 1151–1157, 1159–1164, 1165–1173

Questionnaires
Alcohol Use Disorders Identification Test, 197–206
amphetamine dependence, 151–162, 839–845
Nottingham Health Profile for methadone patients, 707–716
Self-Efficacy, 313–324
self-rating alcohol effects for alcoholism risks, 979–988
Severity of Dependence Scale, 353(L), 839–849
Situational Confidence, 313–324

Raves and drug use, 1317–1325, 1327–1337
Relapse prevention of male problem drinkers, 61–74
Research
and embargo policies, 1237–1239(Ed)
tobacco industry support, 517–520(Ed), 521–529
Research methods
costing addiction services, 1007–1015
ethical issues, 1071–1107
generalizability of smoking studies, 469–472
geographical data, S273–S283
medical statistics and Sir Bradford Hill, 657–666
self-reports, 601–606, 931–937
see also Alcohol research *and* Drugs research
Risk behaviour of drug injectors, 354(L), 813–820, 906#, 1339–1347, 1349–1352, 1457–1465, 1737–1748
Ritanserin for alcohol problems, 939–947, 949–964
Road accidents, alcohol-related *see* Drink-driving
Romania, antismoking laws, 1582#

Scientific societies, membership by tobacco industry scientists, 517–520(Ed), 521–529

Scotland
drug use at dance events, 1317–1325, 1327–1337
mortality of drug injectors, 419–427
Severity of Dependence Scale, 353(L), 839–845
Smoking
and access to medical treatments, 1189–1193
cessation
and cigarette health warnings, 1427–1435
Clinical Practice Guideline, 653–655(Ed)
craving and effect of alcohol, 15–26
saliva cotinine collection methods, 347–351
self-help, 223*
success of patches, 27–31, 207–218
in China, 905#
and co-factors, 397–408
generalizability of studies, 469–472
genetic/environmental factors, 1277–1287
harm reduction by switching to pipe/cigar, 1379*
in Japan, 1023–1033
occasional smokers, 473–480
reward responsibility and cognition, 1773–1782
and social class, S13–S20
workplace bans
puff topography, 607–610
smoking outside, 1361–1368
see also Nicotine *and* Tobacco
Smoking Cessation Clinical Practice Guideline, 653–655(Ed)
Society for Research on Nicotine and Tobacco, 613–633
Society for the Study of Addiction, Honorary Fellows, 766
Spain
alcohol consumption, S21–S31
heroin abuse rates, 1749–1763
Speech and alcohol, 1794*
Sweden
alcohol policies, 859–870
alcohol problems, 1523–1536
Switzerland, hidden population study, 325–334

Tackling Local Drug Markets report, 906#
Teenagers *see* Adolescents
Tobacco
advertising, 1582#
conference, 762#
dependence *see* Nicotine addiction
industry, 133–135(Ed), 763*
and membership of scientific societies, 517–520(Ed), 521–529
litigation, 1582#
provision to poorer countries, 1137–1141, 1380#
public health policies, 133–135(Ed), 232#, S13–S20, S97–S101, 607–610, 1044#, 1151–1157, 1165–1173, 1361–1368
research, 615–633
industry supported, 517–520(Ed), 521–529, 1071–1075, 1423–1426
see also Nicotine *and* Smoking
Traffic accidents, alcohol-related *see* Drink-driving
Training *see* Education and training

United Kingdom
amphetamine prescriptions for drug abusers, 833–838
costing addiction services, 1007–1015
drug treatment services, 373–374(Ed)
Home Office Index, 768#
Institute for the Study of Drug Dependence website, 1380#
national survey of drug misuse, 931–937
Tackling Local Drug Markets report, 906#
volatile substance abuse deaths, 1765–1771
see also Scotland
United States
alcohol
attractiveness and alcohol accessibility, 597–600
consumption from 1979 to 1990, 33–47
drink-driving sanctions, 989–997, 1133–1136
labels, 789–792(Ed)
NIAAA and Harold Hughes, 137–149
preventing trauma trial, S155–S310
prohibition, 1405–1409(Ed)
women, 765*, 1201–1205
drugs
American Council for Drug Education website, 1380#
crack and powder cocaine prices, 1437–1443
history, 137–149, 489*
HIV in overdose victims, 1017–1022
policies, 1123–1131, 1143–1150, 1790*, 1791*
policing strategies, 557–569, 611–613(L), 1038*
students' cannabis use, 571–581
tobacco advertising, 1582#
youth tobacco/alcohol use and law enforcement, 1159–1164

Volatile substance abuse mortality, 1379#, 1765–1771

Women
and addiction, 765*
gender specific etiology, 1265–1276
alcohol, 1792*
and psychiatric problems, 183–196
temperance in Tudor England, 97–111
drug abuse, 492*
cocaine abuse and abruptio placentae, 1547–1551
pre-natal drug exposure, 1123–1131, 1373*, 1547–1551, 1553–1560, 1561–1570, 1571–1579
nicotine withdrawal, 889–902
single gender treatment, 805–812
Workplace
aviation alcohol policies, 539–555, 793–804
responses to alcohol problems, S127–S132
smoking bans, 607–610, 1361–1368
substance abuse policies, 1123–1131
World Health Organization
Alcohol Policy and the Public Good report, S73–S79
benzodiazepines report, 1581#
harm minimization variations, 355#
Programme on Substance Abuse, 1581#

Yates, Fred, obituary, 229
Young people
alcohol
education, S121–S125, 531–537
expectancies, 871–888
majority fallacy, 729–736
criminalization of alcohol/tobacco use, 1159–1164
drugs
cannabis, 279–296, 571–581
concepts of drugs, 847–858
HIV risks of new injectors, 1457–1465
and raves, 1327–1337
and tobacco policies, 1165–1173
see also Adolescents